SGX Pharmaceuticals
Pharmaceutical company that developed structure-guided drug discovery approaches for oncology. Acquired by Eli Lilly in 2008 for approximately $64 million.
Location
San Diego, California, USA
Founded
2002
Investors
1
Categories
biotech, drug-discovery, oncology, acquired
Notes
SGX Pharmaceuticals was a pharmaceutical company focused on structure-guided drug discovery, primarily for oncology applications. The company developed proprietary technologies for identifying and optimizing drug candidates using structural biology approaches.
Acquired by Eli Lilly in 2008 for approximately $64 million. The acquisition brought SGX's structure-guided drug discovery platform and oncology pipeline to Eli Lilly.
The company was part of the Apple Tree Partners portfolio before its acquisition.
Team
- Historical leadership team (company acquired in 2008)
Additional Research Findings
- Apple Tree Partners portfolio company
- Structure-guided drug discovery platform
- Oncology focus
- San Diego, California headquarters
- Acquired by Eli Lilly in 2008 for ~$64 million
- Founded in 2002
Sources
- Eli Lilly Acquisition Announcement
- Apple Tree Partners Portfolio
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apple Tree Partners | New York, USA | biotech-focused | series-aseries-b+2 | 23 |